Home
Leadership
Science
Data
Media
- News
- Videos
Partners
Contact

Videos

Home / Videos

About Us

SIWA’s 318H monoclonal antibody targets a biomarker on cancer cells, senescent cells, and microbially-infected cells. Our initial focus is on life-threatening cancers and related diseases with an unmet medical need (i.e., eligible for FDA Fast-tracking). We expect to file our first IND in late 2022.

Recent News

SIWA Therapeutics Announces Promising Results in New Pancreatic Cancer Study
SIWA Therapeutics, Inc. Appoints Deborah Wince-Smith to Board of Directors
Listen to Ashley Jensen discuss SIWA’s antibody at AACR’s Virtual Conference!

JOIN OUR MAILING LIST

Navigation

Home
Leadership
Science
Data
Media
- News
- Videos
Partners
Contact